^
Association details:
| Biomarker: | FGFR mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | gunagratinib (ICP-192) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations.
Published date:
05/19/2021
Excerpt:
Among the 12 patients with FGF/FGFR gene aberrations who have completed at least one tumor assessment, the overall response rate (ORR) was 33.3%...The disease control rate (DCR) was 91.7% (11 of 12 patients)….Gunagratinib is safe and well-tolerated in patients with advanced solid tumors.
DOI:
10.1200/JCO.2021.39.15_suppl.4092
Trial ID:
